We recently published a list of Was Jim Cramer Right About These 23 Stocks?. In this article, we are going to take a look at ...

The head of one of America's largest pharmaceutical companies says he does not support tariffs on Australian medicines as US President Donald Trump considers more trade restrictions.

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

China is stepping up efforts to reassure U.S. corporate giants like Apple, Pfizer, and Mastercard of its economic potential, ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. With rising ...

Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major ...

BEIJING: China sought to reassure foreign corporate chiefs of the country’s business potential when Vice Premier ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... the direction of the market will largely be determined by President Donald Trump and the Federal Reserve.

"The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India," said President and General Manager Winselow Tucker at Lilly India. Obesity and ...